Skip To Main Content

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit

Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.

Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.

Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.

Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial.

VTE prophylaxis in medically ill patients

Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress

Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress

Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress

Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress

Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress

Key Learnings in Dyslipidemia by Prof. Kausik Ray - 2021 EAS Congress

Odyssey Outcomes - PVD Sub-analysis